Eugene J Schaefer from Bluffton, SC, age 76

Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins
view source
US Patent:

20160237149, Aug 18, 2016
Filed:

Dec 23, 2015
Appl. No.:

14/757691
Inventors:

- Horsham PA, US
- Leiden, NL
Francis Maslanka - Malvern PA, US
Franciscus Johannes Ignatius Nagel - Leiden, NL
James Ryland - Malvern PA, US
Eugene Schaefer - Malvern PA, US
International Classification:

C07K 16/24
Abstract:

Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.

Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins
view source
US Patent:

20140273092, Sep 18, 2014
Filed:

Mar 13, 2014
Appl. No.:

14/207915
Inventors:

- Leiden, NL
- Horsham PA, US
Francis Maslanka - Malvern PA, US
Franciscus Johannes Ignatius Nagel - Leiden, NL
James Ryland - Malvern PA, US
Eugene Schaefer - Malvern PA, US
Assignee:

Janssen Biologics B.V. - Leiden
Janssen Biotech, Inc. - Horsham PA
International Classification:

C07K 16/24
US Classification:

435 696
Abstract:

Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.